All cases showing loss of MLH1 (20% of cases) and PMS2 (25%) expression, and absence of CEA expression (22% of cases) were non-metastatic tumors; most liver metastatic tumors had a positive value of EGFR membranous expression (79% vs. 38% of non-metastatic cases). The gene discussed is EGFR; the disease is metastatic neoplasm.